Vitamin E is a fat soluble antioxidant and as a result it is able to scavenge free radicals derived from oxygen. The premature infant and the retina are likely to be particu larly vulnerable to the deleterious effects of these oxygen derived free radicals, and as a result prophylactic vitamin E has been suggested for the management of retinopathy of prematurity (ROP). However, despite numerous trials, prophylactic supplementation with vitamin E remains controversial. This paper will critically review the use of vitamin E in ROP and consider the risk/benefit relation ship of such treatment in premature infants.
Retinopathy of prematurity (RaP), previously known as retrolental fibroplasia was first described by Terry in 19421 and a beneficial effect of supplementation with vitamin E was first suggested in 1949.2 Since then and up to the pres ent time the role of prophylactic supplementation with vitamin E in Rap has been controversial. In this review the probable function of vitamin E in vivo will be dis cussed, and the theoretical reasons why vitamin E may be particularly important in the premature infant and in Rap considered. The evidence that prophylactic supplements of the vitamin may influence the incidence and severity of Rap will then be critically reviewed.
VITAMIN E
The biological activity of vitamin E is not limited to a single compound but is shared by a number of closely related derivatives of 2 methyl-2-(4', 8', 12' trimeth yltridecyl)-6-chromanol or tocol. These compounds belong to two series which differ in the degree of unsat uration of the phytyl side chain; those which are saturated are termed tocopherols and those with an unsaturated side chain tocotrienols. Within each group, there are four com pounds (designated alpha-, beta-, gamma-, and delta-), which differ according to the number and position of the methyl groups on the chromanol ring. Of these, alpha tocopherol has the greatest biological activity3 and The biological activity of vitamin E results principally from its antioxidant properties.5 Antioxidants are essential to protect molecules and biological systems from oxida tive damage by oxygen-derived free radicals. These are chemical species with an unpaired electron which as a result are highly reactive and able to react with many mol ecules in living cells, producing in most cases another free radical and thereby generating a chain reaction. Oxygen derived free radicals, such as the superoxide anion radical or hydroxyl radical, are produced as a result of many bio logical reactions, including oxidative phosphorylation, enzymatic reactions, inflammatory processes, detoxifica tion of drugs via the cytochrome P450 system, and as the principal process by which neutrophils kill bacteria.6 If production of these highly reactive free radical species is allowed to proceed unchecked, they are able to oxidise a variety of biologically important molecules and cause membrane and cell damage. Antioxidant defences can be divided into two groups: firstly preventative antioxidants such as catalase and glutathione peroxidase which prevent the formation of free radical species, and secondly chain breaking antioxidants such as superoxide dismutase, ascorbate, urate, and vitamin E which trap oxygen-derived free radicals and halt the chain reaction.
The importance of vitamin E lies in the fact that it is the only well recognised, lipid-soluble, chain-breaking anti oxidant.5 It is able to trap radicals formed as a result of the oxidation of the unsaturated fatty acids of membrane phospholipids and thereby prevent lipid peroxidation.
Vitamin E is likely, therefore, to be important for main taining the integrity and stability of biological membranes.
THE EYE
There are a number of features which make the retina particularly susceptible to autoxidation by oxygen-derived free radicals and, therefore, particularly vulner able to a deficiency of antioxidants such as vitamin E.7 The retina is served with a plentiful supply of oxygen, has an abundant supply of mitochondria, and an unusually high rate of oxidative metabolism. Thus, an increased leak of oxygen-derived free radicals may occur and result in increased lipid peroxidation. The membranes of the rod outer segments are particularly vulnerable to peroxidation as more than 65% of the membrane fatty acids are poly unsaturated, which is the highest proportion found in any vertebrate tissue examined to date. The retina is also fre quently exposed to intense light which can be phototoxic. Light of wavelength greater than 400 nm cannot of itself break covalent bonds but damage may result from a ther mal mechanism, or through a photosensitising process which may also produce oxygen-derived free radicals.
There are at least three conditions of the eye where a deficiency of vitamin E has either been implicated and/or treatment with vitamin E has been suggested. Firstly the well documented retinopathy associated with a severe and chronic deficiency of vitamin E has been described both in man 8 and experimental animals.9 Secondly, treatment with antioxidants including vitamin E is reported to be effective in limiting cataract formation 10 and thirdly vitamin E ther apy has been suggested for the management of ROP.
THE NEWBORN
The newborn and particularly the premature infant is theoretically at risk of damage from oxygen-derived free radicals because of both exposure to increased concen trations of oxygen derived free radicals and also reduced antioxidant defences. Thus at birth an infant abruptly enters a relatively hyperoxic extrauterine environment with the alveoli of the lung being exposed to an oxygen tension approximately five times greater than that during intrauterine development. The situation is further exac erbated in many small premature infants, where as part of the management of the respiratory distress syndrome they are exposed to increased concentrations (up to lOO%) of oxygen. Premature infants are also frequently exposed to high intensity illumination. In addition many studies have documented reduced serum concentrations of vitamin E in the newborn.
I 1 -13 Initially it was thought that this resulted from impaired permeability of the placenta to alpha-toco pherol but it is now thought to be a function of a reduced transport capacity in the blood of the neonate.14 In the normal breast fed newborn, serum concentrations of vita min E typically increase to within the normal adult refer ence range within two to three weeks, whereas it takes much longer to achieve these concentrations in the pre mature infant. As discussed above the net result of these factors is likely to be increased lipid peroxidation of mem brane lipids. Among the products of in vivo lipid perox idation are the volatile hydrocarbons, ethane and pentane which are eliminated in expired air. 15 It has been reported that the excretion of these hydrocarbons is increased approximately tenfold in infants (mean age of lO days) compared with adults, 16 confirming that there is indeed an increased rate of lipid peroxidation in the newborn.
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As a consequence of these observations, vitamin E ther apy has been suggested for a number of conditions of the newborn where oxygen derived free radicals have been implicated e.g. bronchopulmonary dysplasia and intraven tricular haemorrhage in addition to ROP. There is, how ever, no evidence that vitamin E reduces the incidence of bronchopulmonary dysplasia,17 whereas the situation appears to be more encouraging in intraventricular haemorrhage. 1 8 -21
Observations on the ultrastructure of the developing ret ina have provided an explanation for the development of ROP and a possible role for vitamin E. The history of ROP and the controversy regarding vita min E therapy in this condition will now be considered.
HISTORY OF RETINOPATHY OF PREMATURITY
As mentioned previously, the original description of ROP 
VITAMIN E AND RETINOPATHY OF PREMATURITY
The first non-randomised trial of vitamin E in ROP was carried out in 19492 which suggested that the vitamin might have a beneficial effect. Since then numerous trials of vitamin E supplementation have been carried out with conflicting results. Some reported no significant effect of vitamin E, 25 -2R others a significant decrease in severity but not in incidence,29 -33 whereas others reported a significant decrease in both incidence and severity of ROP. 34.35 These differences in results are not altogether surprising when one considers the relatively small numbers of patients in many of the studies, the problems associated with low incidence events and the number of variables involved.
The variables will include patient selection; dosage of vitamin E in controls (none or small doses); methods of administration of vitamin E (oral, intramuscular or intra venous); the dose, scheduling and duration of vitamin E treatment; the plasma vitamin E concentrations achieved and methods of statistical analysis. Table show that there was no statistically significant reduction in risk ofROP following vitamin E treatment for either all infants with ROP or those with severe ROP. The results were therefore' consistent with no effect at all'. On the other hand if vitamin E was effective, the relative risk for all infants was 0.95 and, therefore, no more than 5% of all premature infants would benefit from vitamin E supplementation.
A randomised trial in a total of 755 infants was recently reported by Johnson et al.38 after Law et al.36 had com pleted their analysis. They reported a significant decrease in the incidence of ROP in the treated group, and although they found no significant decrease of severe ROP, they stated that the progression from moderate to severe ROP was less frequent following vitamin E treatment.
Despite the inconclusive nature of these studies, sup plementation with prophylactic vitamin E might be acceptable if no hazard was involved. Thus both the inci dence of ROP and the risklbenefit relationship of giving prophylactic vitamin E must be considered.
INCIDENCE OF SEVERE ROP
In 1982 Phelps estimated that in the United States, 22,000 infants of < 1,500 g would survive and of these 2,000 (9.5%) would have severe ROP with cicatricial sequelae and 500 (2.3%) would be blind. 39 
POSSIBLE RISKS ASSOCIATED WITH VITAMIN E ADMINISTRATION
There have been reports which suggest that there is an Since discontinuation of the preparation the condition dis appeared. The mechanism underlying this syndrome appears to be related to the carrier (polysorbate 80) used in the preparation rather than to vitamin E itself. 45 and also with the statement of Law et al16 that 'Future priority must be to exclude hazard rather than confirm benefi t'.
CONCLUSIONS

